v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Revenue [1] $ 652,520 $ 444,328 $ 1,148,766 $ 927,977
Expenses        
Cost of revenue [1] 571,684 343,943 984,156 725,121
Selling, general and administrative expenses [1] 68,831 75,209 141,649 153,618
Depreciation and amortization expenses 21,566 23,141 43,121 47,199
Loss on lease termination 0 0 0 1,906
Change in fair value of contingent consideration 0 3,206 0 2,926
Operating expenses 662,081 445,499 1,168,926 930,770
Operating loss (9,561) (1,171) (20,160) (2,793)
Interest income 703 1,084 1,717 2,358
Interest expense (16,859) (11,601) (33,727) (21,986)
Gain (loss) from equity method investees (41) 197 (52) 178
Loss on option exercise 0 (196) 0 (52,544)
Extinguishment of Series A Preferred Stock and other refinancing fees 0 (9,000) 0 (9,000)
Other income (expense), net 109 (35) 851 (83)
Loss before income taxes (25,649) (20,722) (51,371) (83,870)
Provision for (benefit from) income taxes 2,715 (825) 3,625 645
Income (loss) before preferred dividends and accretion of Series A Preferred Stock (28,364) (19,897) (54,996) (84,515)
Dividends and accretion of Series A Preferred Stock 0 (31,193) 0 (38,825)
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (28,364) (51,090) (54,996) (123,340)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted $ (28,364) $ (51,090) $ (54,996) $ (123,340)
Loss per common share        
Basic (in dollars per share) $ (0.25) $ (0.44) $ (0.49) $ (1.07)
Diluted (in dollars per share) $ (0.25) $ (0.44) $ (0.49) $ (1.07)
Weighted-average common shares outstanding        
Basic (in shares) 112,542 115,882 112,225 115,600
Diluted (in shares) 112,542 115,882 112,225 115,600
Comprehensive loss        
Net loss attributable to common shareholders of Evolent Health, Inc. $ (28,364) $ (51,090) $ (54,996) $ (123,340)
Other comprehensive loss, net of taxes, related to:        
Foreign currency translation adjustment 0 22 (1,002) 46
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. $ (28,364) $ (51,068) $ (55,998) $ (123,294)
[1] See Note 17 for amounts attributable to unconsolidated related parties included in these line items.